ByHeart Recalls All Baby Formula Amid Growing Botulism Cases

An outbreak of infant botulism in the United States has prompted ByHeart, a manufacturer of organic baby formula, to recall all of its products. This decision follows the hospitalization of at least 15 infants across 12 states who consumed the formula since August 9, 2023. Health officials have not reported any fatalities linked to the outbreak.

Initially, ByHeart recalled two specific lots of its formula on November 10, 2023, but subsequently expanded the recall to include all products sold nationwide. This comprehensive action affects ByHeart Whole Nutrition Infant Formula and Anywhere Pack pouches of powdered formula. The company sells approximately 200,000 cans of infant formula each month through various retailers, including Target, Walmart, Albertsons, and Whole Foods.

Dr. Devon Kuehn, ByHeart’s chief medical officer, advised parents and caregivers to “immediately discontinue use and dispose of the product” to prevent further illness. Despite the recall, officials noted that no unopened products tested positive for the botulism-causing bacteria.

Investigation and Health Risks

The bacteria responsible for the toxin is prevalent in the environment, and could originate from sources beyond the formula itself. ByHeart emphasized its commitment to safety, stating, “This action underscores ByHeart’s core mission: protecting babies above all else.” The company is collaborating closely with the U.S. Food and Drug Administration (FDA) during this recall process.

California health officials confirmed that a sample from an open can of ByHeart formula fed to a sick infant contained the hazardous bacteria. In response, the FDA has been investigating 84 cases of infant botulism reported since August, with 15 of those cases involving ByHeart products. The agency highlighted that ByHeart formula is “disproportionately represented among sick infants” considering it accounts for an estimated 1% of all infant formula sales in the United States.

The illnesses have been reported in several states, including Arizona, California, Illinois, Kentucky, Minnesota, North Carolina, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, and Washington. Health officials are still working to identify any additional sources of exposure, but no other infant formula brands have been implicated.

Understanding Infant Botulism

Infant botulism, though rare, poses severe health risks for babies under one year of age due to their immature gut microbiomes. The condition arises when infants ingest bacteria that produce spores, leading to toxin production in their intestines. Symptoms can include constipation, poor feeding, drooping eyelids, muscle weakness, difficulty swallowing, and respiratory issues. Immediate medical attention is critical for affected infants.

The only treatment available for this infection is BabyBIG, an intravenous medication derived from the blood plasma of individuals immunized against botulism.

The implications of the recall extend beyond the United States, raising questions about its impact on Canadian consumers. As of now, it is unclear whether the recall affects ByHeart products sold in Canada or if there have been any reported cases linked to the formula there. Global News has reached out to Health Canada for clarification and is awaiting a response.

In addition to the recall, ByHeart has committed to testing each batch of its formula with an independent third-party laboratory. The company is also granting health officials full access to its facilities and sharing results with regulators as they become available.

This situation underscores the importance of vigilance in infant nutrition and the swift action necessary to address potential health hazards.